Consensus guidelines for the diagnosis and management of isolated sulfite oxidase deficiency and molybdenum cofactor deficiencies.
Level 5 - mechanism / opinion, no new human data
Clinical practice guideline based on expert consensus and a systematic literature search in ultra-rare diseases with minimal direct trial evidence.
PubMed 38627985 · doi:10.1002/jimd.12730
What was done
An expert panel developed consensus clinical practice guidelines for the diagnosis and management of four ultra-rare sulfite intoxication disorders (isolated sulfite oxidase deficiency and molybdenum cofactor deficiency types A, B, and C) based on expert opinion and a systematic literature search.
What was found
The abstract provides no numerical data, study counts, or quantitative treatment effects. It notes that clinical presentation is typically non-specific acute neonatal encephalopathy with high early mortality leading to dystonic cerebral palsy, that diagnostic delays and management variability are common, and that synthetic cPMP (fosdenopterin) is available for MoCD type A despite a very limited clinical evidence base.
Why it matters
This guideline provides a standardized clinical framework to expedite diagnosis, optimize supportive care, and guide the rational use of disease-modifying treatment like fosdenopterin in ultra-rare, severe metabolic disorders.
Limits
The abstract reports no sample sizes, specific study inclusion counts, or quantitative outcome metrics. The underlying evidence base is explicitly limited, requiring substantial reliance on expert opinion rather than high-certainty randomized trials.
Cited by
- context Molybdenum acts as an antidote to counteract adverse reactions and hangover-like symptoms from sulfites and sulfur sensitivity.